Hans-Peter Gerber
Chief Scientific Officer Sutro Biopharma
Dr. Hans-Peter Gerber brings 30 years of R&D experience in oncology drug development, specializing in ADCs, redirected T-cell targeting compounds (bispecifics), and adoptive T-cell therapies (TCR-T and CAR-T cells). He has built successful drug development teams across pharma, biotech, and startups, overseeing preclinical development with low clinical attrition rates. Notably, he has contributed to the development of 6 of the 15 approved ADCs.
In September 2023, Hans-Peter joined Sutro Biopharma as CSO, leading a research team of 80 FTEs. He co-founded Codeable Therapeutics in 2022, focusing on next-generation ADCs that induce immunogenic cell death, and successfully secured seed funding in 2023.
Seminars
Tuesday 4th November 2025
Panel Discussion: Delving into Novel Design & Development to Strive for Next-Generation ADCs Providing Long-Term Benefit to Patients
5:00 pm
- Evaluating the landscape of ADC therapies: is the risk of innovation now lower than the risk of irrelevancy?
- Assessing hurdles and opportunities to achieve differentiated ADC profiles in crowded ADC payload and target fields
- Delving into novel ADC payloads: what new MoAs are emerging and what has been demonstrated so far?
- Understanding perspectives on the future of ADC development across ADC design, targeting, and precision medicine approaches
